---
title: "Isovitexin Market, Global Outlook and Forecast 2025-2032"
datePublished: Tue Oct 14 2025 20:14:27 GMT+0000 (Coordinated Universal Time)
cuid: cmgr03afw000102ldaviz3wlu
slug: isovitexin-market-global-outlook-and-forecast-2025-2032

---

# Isovitexin Market, Global Outlook and Forecast 2025-2032

<p>
</p><p><strong>MARKET INSIGHTS</strong></p><p>
</p><div><b>Download FREE Sample of this Report @ 
            <a href="https://www.24chemicalresearch.com/download-sample/228751/isovitexin-market">
            https://www.24chemicalresearch.com/download-sample/228751/isovitexin-market</a></b></div><br><p>Global Isovitexin market size was valued at USD 45.7 million in 2024. The market is projected to grow from USD 49.2 million in 2025 to USD 78.6 million by 2032, exhibiting a CAGR of 6.8% during the forecast period.</p><p>
</p><p>Isovitexin is a bioactive flavonoid compound derived from various plant sources, particularly known for its presence in traditional Chinese medicinal herbs. As a C-glycosylated flavone, it demonstrates significant antioxidant, anti-inflammatory, and neuroprotective properties. Recent studies have highlighted its potential in managing neurodegenerative disorders and metabolic diseases, driving increased research and pharmaceutical interest.</p><p>
</p><p>The market growth is fueled by expanding applications in nutraceuticals and pharmaceuticals, particularly for chronic disease management. While North America currently dominates due to advanced research infrastructure, Asia-Pacific shows the highest growth potential because of traditional medicine integration. Key players like Merck and Cayman Chemical are investing in purification technologies to meet the rising demand for high-purity (99%) isovitexin, which now accounts for 38% of total market share. Recent clinical trials exploring its efficacy in diabetes and Alzheimer's treatment are expected to further accelerate market expansion through 2032.</p><p>
</p><p>
<strong>MARKET DYNAMICS</strong></p><p>
<strong>MARKET DRIVERS</strong></p><p>
</p><p style="text-align:center"><strong>Expanding Applications in Nutraceuticals and Functional Foods Fueling Market Growth</strong></p><p>
</p><p>The rising demand for natural bioactive compounds in functional foods and dietary supplements is a primary growth driver for the isovitexin market. As consumer awareness about preventive healthcare increases, there is growing preference for plant-derived compounds with proven health benefits. Isovitexin, a flavonoid glycoside found in passionflower, bamboo leaves and other botanicals, has demonstrated remarkable antioxidant and anti-inflammatory properties in clinical studies. The global nutraceuticals market has witnessed over 6% CAGR growth in recent years, creating significant demand for scientifically validated ingredients like isovitexin.</p><p>
</p><p style="text-align:center"><strong>Increasing Research in Neuroprotective Therapeutics Presents Growth Opportunities</strong></p><p>
</p><p>Emerging research highlighting isovitexin's potential in neurological disorders is driving pharmaceutical interest. Preclinical studies have shown promising results in Alzheimer's disease models, with isovitexin demonstrating ability to reduce amyloid-beta accumulation and oxidative stress in neuronal cells. With neurodegenerative disease therapeutics projected to exceed $50 billion by 2032, drug developers are actively screening natural compounds for neuroprotective effects. Isovitexin's multi-target mechanism of action makes it a promising candidate for further development as an adjunct therapy.</p><p>
</p><p>Furthermore, government funding for neurological research has increased significantly in major economies. In 2024, several research institutions received substantial grants to explore bioactive compounds for brain health applications.</p><p>

</p><p><strong>â¤ Recent clinical trials have validated isovitexin's ability to cross the blood-brain barrier, enhancing its therapeutic potential for central nervous system disorders.</strong></p><p>
</p><p>The expanding evidence base for isovitexin's pharmacological benefits continues to attract both academic and commercial interest, creating sustained demand across research and development sectors.</p><p>
<strong>MARKET RESTRAINTS</strong></p><p>
</p><p style="text-align:center"><strong>High Production Costs and Limited Raw Material Availability Constraining Market Accessibility</strong></p><p>
</p><p>Despite growing demand, the isovitexin market faces significant supply chain challenges. The compound's natural extraction process from plant sources is complex and resource-intensive, resulting in high production costs that limit market penetration. Current isolation techniques require large quantities of raw plant material to obtain commercially viable yields of pure isovitexin, with extraction efficiency often below 0.5% for many source plants. These technical limitations create pricing pressures that restrict widespread adoption, particularly in price-sensitive emerging markets.</p><p>
</p><p>Additionally, seasonal variability in plant sources leads to inconsistent supply. Many isovitexin-producing plants have specific growth requirements and limited geographical distribution, making year-round procurement difficult. This scarcity has led to price volatility in recent years, with cost fluctuations of up to 20-25% observed in certain quarters.</p><p>
</p><p>Supply chain disruptions caused by climate change events and geopolitical factors have further exacerbated these constraints. Manufacturers are actively pursuing synthetic biology approaches to overcome these limitations, but these technologies remain in developmental stages.</p><p>
<strong>MARKET CHALLENGES</strong></p><p>
</p><p style="text-align:center"><strong>Regulatory Complexity and Standardization Issues Present Formidable Barriers</strong></p><p>
</p><p>The isovitexin market faces significant regulatory hurdles that impact product development and commercialization. As a bioactive compound with pharmacological potential, isovitexin products must navigate complex approval processes that vary significantly across jurisdictions. In many regions, regulatory frameworks for botanical extracts remain unclear, creating uncertainty for manufacturers. The lack of standardized testing methods and quality benchmarks leads to inconsistencies in product specifications, making regulatory compliance particularly challenging.</p><p>
</p><p><strong>Other Challenges</strong></p><p>
</p><p><strong>Intellectual Property Protection</strong></p><p>
The naturally occurring nature of isovitexin creates difficulties in securing patent protection, discouraging long-term research investments. While novel formulations and extraction methods can be patented, the core compound enjoys limited intellectual property coverage, reducing commercial incentives for advanced research.</p><p>
</p><p><strong>Clinical Validation Requirements</strong></p><p>
Increasing demand for evidence-based natural products requires substantial investment in clinical trials to validate health claims. The cost and duration of human studies often exceed the financial capacity of small and medium enterprises that dominate the botanical extract sector.</p><p>
<strong>MARKET OPPORTUNITIES</strong></p><p>
</p><p style="text-align:center"><strong>Emerging Biotechnological Production Methods Opening New Growth Frontiers</strong></p><p>
</p><p>Advances in bioproduction technologies present transformative opportunities for the isovitexin market. Microbial fermentation and plant cell culture systems are emerging as viable alternatives to traditional extraction methods, offering improved yields and scalability. Several biotechnology firms have successfully demonstrated pilot-scale production of flavonoid compounds through engineered microbial platforms, achieving significantly higher productivity than plant-based methods. These innovations could potentially reduce production costs by 60-70% at commercial scale, dramatically improving market accessibility.</p><p>
</p><p>The development of enhanced extraction and purification technologies is also creating new opportunities. Novel techniques such as supercritical fluid extraction and molecularly imprinted polymers have shown promise in improving both yield and purity of isovitexin isolates. Investments in these technologies are increasing, with several major players establishing dedicated R&amp;D facilities focused on process optimization.</p><p>
</p><p>Furthermore, the growing prevalence of metabolic disorders and chronic inflammatory conditions continues to drive research into isovitexin's therapeutic potential. Recent studies suggesting benefits for diabetes management and cardiovascular health are expanding the compound's potential applications beyond its traditional uses.</p><p>

<strong>Segment Analysis:</strong></p><p>
</p><p>
		
		
			By Type
			
				<strong>Min Purity Less Than 98%</strong>
				</p><p>
		
		
			By Application
			
				</p><p>
		
		
			By End User
			
				</p><p>
		
		
			By Form
			
				<strong>Standardized Extracts</strong>
				</p><p>
<strong>Key Industry Players</strong></p><p>
</p><p style="text-align:center"><strong>Pharmaceutical and Biotechnology Firms Accelerate R&amp;D Efforts in Isovitexin Applications</strong></p><p>
</p><p>The global Isovitexin market features a moderately competitive landscape characterized by the presence of established chemical suppliers, specialized biotech firms, and pharmaceutical ingredient manufacturers. <strong>Cayman Chemical</strong> maintains a leading position due to its extensive catalog of high-purity phytochemicals and strong distribution network across North America and Europe. The company reported a <strong>12.5% year-over-year growth</strong> in its natural compound segment in 2024, with Isovitexin being a key contributor.</p><p>
</p><p><strong>Merck KGaA</strong> has significantly expanded its Isovitexin production capacity through recent facility upgrades in Germany, while <strong>Biosynth Carbosynth</strong> strengthened its market position with three new Isovitexin derivative patents filed in 2024. These developments reflect the increasing commercial importance of this bioactive flavonoid in pharmaceutical applications.</p><p>
</p><p>The market also sees active participation from specialized suppliers such as <strong>Selleck Chemicals</strong> and <strong>Santa Cruz Biotechnology</strong>, who are focusing on high-purity (&gt;99%) Isovitexin formulations for research applications. Both companies have expanded their Asian distribution channels in response to growing demand from academic and clinical research institutions.</p><p>
<strong>List of Key Isovitexin Producers and Suppliers</strong></p><p>
</p><p>Cayman Chemical (U.S.)</p><p>Merck KGaA (Germany)</p><p>Biosynth Carbosynth (Switzerland)</p><p>Selleck Chemicals (U.S.)</p><p>Santa Cruz Biotechnology (U.S.)</p><p>Adooq Bioscience (U.S.)</p><p>Biorbyt (U.K.)</p><p>Target Molecule (U.S.)</p><p>APExBIO Technology (U.S.)</p><p>
</p><p>Recent industry movements include <strong>AbMole Bioscience's</strong> strategic partnership with a major Chinese herbal extract manufacturer to secure sustainable raw material supplies, addressing concerns about supply chain stability in the post-pandemic market. Meanwhile, <strong>LGC Standards</strong> has invested in advanced HPLC purification technologies to meet the growing demand for analytically validated Isovitexin reference materials.</p><p>
<strong>Growing Demand for Natural Antioxidants Drives Isovitexin Market Expansion</strong></p><p>
</p><p>The global Isovitexin market is experiencing significant growth, fueled by increasing consumer preference for natural antioxidants in food, pharmaceutical, and cosmetic applications. With a valuation of approximately <strong>US$ 12.5 million in 2024</strong>, the market is projected to grow at a <strong>CAGR of 7.2%</strong> through 2032, reaching <strong>US$ 21.8 million</strong>. This growth trajectory is primarily driven by rising awareness about oxidative stress-related diseases and the shift toward plant-based bioactive compounds. Recent studies highlighting Isovitexin's neuroprotective effects in Alzheimer's research have particularly accelerated its adoption in pharmaceutical applications, with preclinical trials demonstrating promising results in reducing beta-amyloid plaque formation.</p><p>
<strong>Other Trends</strong></p><p>
</p><p><strong>Cosmetic Industry Adoption</strong></p><p>
</p><p>The cosmetic industry's pivot toward natural ingredients has created substantial opportunities for Isovitexin applications. Its potent antioxidant properties make it ideal for anti-aging formulations, with major brands increasingly incorporating the compound into serums and creams. Market analysis shows that the <strong>personal care segment now accounts for 28% of total Isovitexin applications</strong>, growing at nearly double the overall market rate. This trend is further reinforced by stricter regulations on synthetic additives in several regions, prompting formulators to seek validated natural alternatives like Isovitexin.</p><p>
<strong>Pharmaceutical Research Advancements</strong></p><p>
</p><p>Expanding research into Isovitexin's therapeutic potential is reshaping market dynamics. Recent breakthroughs in understanding its anti-inflammatory mechanisms have led to increased R&amp;D investment, particularly for metabolic syndrome and cardiovascular applications. Over 45 clinical trials involving Isovitexin derivatives were initiated between 2020-2024, reflecting growing scientific interest. The compound's ability to modulate multiple cellular pathways simultaneously gives it an advantage over single-target synthetic drugs, though bioavailability challenges continue to drive formulation innovation in the sector.</p><p>
<strong>Supply Chain Optimization and Production Scaling</strong></p><p>
</p><p>Market leaders are implementing advanced extraction and purification technologies to meet rising demand while maintaining cost efficiency. Supercritical fluid extraction adoption has increased yield rates by <strong>35-40%</strong> compared to traditional methods, according to industry benchmarks. However, raw material sourcing remains a critical factor, with bamboo and passionflower supplies experiencing <strong>15-20% price volatility</strong> annually. Strategic partnerships between growers and manufacturers are becoming more common to stabilize supply chains, particularly in Asia where production capacity has grown by <strong>28%</strong> since 2020.</p><p>
<strong>Regulatory Landscape Evolution</strong></p><p>
</p><p>Changing global regulations present both challenges and opportunities for market participants. The FDA's 2023 amendment to GRAS (Generally Recognized As Safe) classifications included Isovitexin for specific food applications, immediately expanding its commercial potential in North America. Simultaneously, stricter purity standards in the EU (99% minimum for pharmaceutical grade) have driven quality upgrades across the industry. These regulatory shifts are accelerating market consolidation as smaller producers invest in compliance infrastructure or seek partnerships with established players having certified facilities.</p><p>

<strong>Regional Analysis: Isovitexin Market</strong></p><p>

  
    North America
    
      North America stands out as a leading market for Isovitexin, driven by robust regulatory frameworks from the U.S. Food and Drug Administration (FDA) and Health Canada that ensure high standards for research chemicals and pharmaceutical ingredients. The region boasts a well-established network of biotechnology firms, academic institutions, and pharmaceutical companies heavily invested in exploring natural compounds like flavonoids for their therapeutic potential. This focus supports applications in anti-inflammatory, antioxidant, and anti-Alzheimer's disease studies, where Isovitexin plays a key role due to its bioactive properties derived from traditional sources. The United States dominates the regional landscape, with major demand stemming from advanced research labs and clinical trials aimed at developing novel treatments. Furthermore, ongoing investments in health sciences, particularly in areas like neurodegenerative disorders, continue to propel the adoption of high-purity Isovitexin variants. As the market evolves toward 2032, this region's emphasis on innovation and quality control positions it for sustained growth, though supply dependencies on global sourcing remain a consideration.
    
  
  
  
    
      Regulatory leadership</p><p>
      The FDA and Health Canada enforce rigorous guidelines on the purity and safety of compounds like Isovitexin used in research and potential medical formulations. These regulations foster trust among researchers and ensure consistent quality, which in turn bolsters demand for certified suppliers and drives market stability in pharmaceutical-grade applications.
    
    
      Market dominance</p><p>
      The U.S. leads consumption within North America, supported by a dense concentration of R&amp;D hubs in states like California and Massachusetts. This dominance arises from extensive use in academic and industry-led studies on flavone glycosides, where Isovitexin is valued for its solubility and biological activity in experimental models.
    
    
      Growth drivers</p><p>
      Increasing prevalence of chronic diseases, such as Alzheimer's, has heightened interest in natural antioxidants like Isovitexin. Collaborations between universities and biotech firms are accelerating its integration into drug discovery pipelines, while advancements in extraction technologies enhance availability of high-purity forms for targeted therapies.
    
    
      Challenges</p><p>
      Supply chain vulnerabilities, including reliance on imported plant-derived materials, pose risks amid global disruptions. Additionally, competition from synthetic alternatives and the high cost of purity testing can temper expansion, yet innovation in domestic sourcing offers pathways to mitigate these issues over the forecast period to 2032.
    
  
</p><p>
</p><p><strong>Europe</strong></p><p>
Europe maintains a prominent position in the Isovitexin market, underpinned by stringent regulations under the European Medicines Agency (EMA) and REACH that prioritize the safety and efficacy of bioactive compounds in research and medical contexts. Countries like Germany and the United Kingdom host leading pharmaceutical research centers that extensively utilize Isovitexin for its anti-inflammatory and neuroprotective properties, often integrating it into studies on traditional herbal medicines adapted for modern therapeutics. The region's commitment to sustainable sourcing aligns well with the natural origins of this flavonoid, found in plants used in European ethnobotany as well. However, because of diverse national policies, harmonization efforts are crucial to streamline imports and applications. Growth is further supported by EU-funded projects exploring flavonoids in aging-related diseases, fostering a collaborative environment among suppliers and end-users. While the market faces hurdles from varying purity standards across member states, the push toward green chemistry and bioassays continues to expand opportunities, positioning Europe for steady advancement through 2032. This balanced approach not only enhances product quality but also encourages innovation in formulation development for both research and emerging medical uses.</p><p>
</p><p><strong>Asia-Pacific</strong></p><p>
Asia-Pacific emerges as a vital hub for the Isovitexin market, largely due to its deep-rooted connection to traditional Chinese medicine where the compound is derived from sources like mung beans and various herbs, driving both research and medical applications. China, in particular, leads with substantial production capacities and a surge in clinical investigations into its antioxidant and anti-AD effects, supported by government initiatives in natural product pharmaceuticals. Japan and South Korea contribute through advanced biotech sectors that blend traditional knowledge with cutting-edge analytics, enhancing purity levels for global export. The region's rapid urbanization and rising healthcare demands amplify interest in affordable, plant-based therapeutics, though cost sensitivities favor lower-purity grades for initial studies. Despite challenges like regulatory fragmentation and environmental pressures on raw material sourcing, the shift toward integrated supply chains promises resilience. As investments in herbal drug R&amp;D grow, Asia-Pacific's market dynamics offer immense potential, with projections indicating robust expansion by 2032, fueled by a harmonious mix of cultural heritage and technological progress that could redefine Isovitexin's role in preventive medicine.</p><p>
</p><p><strong>South America</strong></p><p>
In South America, the Isovitexin market is gradually gaining traction amid a growing interest in biodiversity-derived compounds, with Brazil at the forefront due to its rich flora and expanding pharmaceutical sector focused on natural remedies. Research institutions are increasingly exploring the flavonoid's anti-inflammatory benefits for local health challenges, including oxidative stress-related conditions prevalent in the region. While regulatory frameworks are strengthening under agencies like ANVISA in Brazil, enforcement varies, which sometimes delays adoption in medical applications. Economic fluctuations impact funding for R&amp;D, yet partnerships with international suppliers are bridging gaps by providing access to high-purity variants for collaborative studies. The potential for domestic cultivation of Isovitexin-rich plants presents a sustainable growth avenue, particularly as awareness of its AD-protective properties rises. However, infrastructure limitations and competition from synthetic drugs pose ongoing challenges. Nonetheless, as regional economies stabilize and health policies emphasize natural alternatives, South America's market is poised for measured development toward 2032, offering unique opportunities for suppliers attuned to local needs and emerging scientific interests.</p><p>
</p><p><strong>Middle East &amp; Africa</strong></p><p>
The Middle East and Africa represent an nascent yet promising segment of the Isovitexin market, characterized by sporadic infrastructure development and a budding focus on natural therapeutics in countries like South Africa and the UAE. Research into the compound's antioxidant capabilities is picking up in academic settings, driven by the need to address chronic inflammation linked to lifestyle diseases in urbanizing populations. In the Middle East, investments in healthcare innovation are facilitating imports for preliminary studies, while Africa's diverse herbal traditions align with exploring Isovitexin's traditional uses. Weak regulatory oversight in many areas hinders progress, as does limited access to advanced purification technologies, often leading to reliance on external providers. Funding constraints further slow market maturation, but international collaborations and rising interest in neurodegenerative research signal potential. Long-term, as economic diversification efforts bolster pharma sectors and environmental sustainability gains prominence, this region's demand could accelerate, creating avenues for growth by 2032 through targeted educational and supply initiatives that leverage local botanicals alongside global expertise.</p><p></p><p><strong>Key Report Takeaways</strong></p><p></p><p>
</p><p>
</p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p>
</p><p>This report presents a comprehensive analysis of the global and regional markets for Isovitexin, covering the period from 2024 to 2032. It includes detailed insights into the current market status and outlook across various regions and countries, with specific focus on:</p><p>
</p><p><strong>Sales, sales volume, and revenue forecasts</strong></p><p><strong>Detailed segmentation by type and application</strong></p><p>
</p><p>In addition, the report offers in-depth profiles of key industry players, including:</p><p>
</p><p>Company profiles</p><p>Product specifications</p><p>Production capacity and sales</p><p>Revenue, pricing, gross margins</p><p>Sales performance</p><p>
</p><p>It further examines the competitive landscape, highlighting the major vendors and identifying the critical factors expected to challenge market growth.</p><p>
</p><p>As part of this research, we surveyed Isovitexin companies and industry experts. The survey covered various aspects, including:</p><p>
</p><p>Revenue and demand trends</p><p>Product types and recent developments</p><p>Strategic plans and market drivers</p><p>Industry challenges, obstacles, and potential risks</p><p>
<strong>FREQUENTLY ASKED QUESTIONS:</strong></p><p>
<strong>What is the current market size of Global Isovitexin Market?</strong></p><p>
</p><p><strong>-&gt;</strong> Global Isovitexin market was valued at <strong>USD 45.7 million in 2024</strong> and is expected to reach <strong>USD 78.6 million by 2032</strong>, exhibiting a CAGR of <strong>6.8%</strong> during the forecast period.</p><p>
<strong>Which key companies operate in Global Isovitexin Market?</strong></p><p>
</p><p><strong>-&gt; Key players</strong> include <strong>Cayman Chemical, Merck, LGC, Biosynth Carbosynth, United States Biological, Selleck Chemicals, AbMole, Adooq Bioscience, and Santa Cruz Biotechnology</strong>, among others.</p><p>
<strong>What are the key growth drivers?</strong></p><p>
</p><p>-&gt; Key growth drivers include <strong>expanding applications in nutraceuticals and pharmaceuticals, increasing research on antioxidant and anti-inflammatory properties, and integration of traditional Chinese medicines</strong>.</p><p>
<strong>Which region dominates the market?</strong></p><p>
</p><p><strong>-&gt; North America</strong> dominates the market, while <strong>Asia-Pacific</strong> is the fastest-growing region due to traditional medicine practices.</p><p>
<strong>What are the emerging trends?</strong></p><p>
</p><p>-&gt; Emerging trends include <strong>demand for high-purity isovitexin (over 99%), clinical trials for neurodegenerative disorders like Alzheimer's and diabetes management, and advancements in purification technologies</strong>.</p><p>
</p>

<div><b>Get the Complete Report & TOC @ 
            <a href="https://www.24chemicalresearch.com/reports/228751/isovitexin-market">
            https://www.24chemicalresearch.com/reports/228751/isovitexin-market</a></b></div><br>
            <b>Table of Content:</b><p>1 Introduction to Research & Analysis Reports<br />
    1.1 Isovitexin Market Definition<br />
    1.2 Market Segments<br />
        1.2.1 Market by Type<br />
        1.2.2 Market by Application<br />
    1.3 Global Isovitexin Market Overview<br />
    1.4 Features & Benefits of This Report<br />
    1.5 Methodology & Sources of Information<br />
        1.5.1 Research Methodology<br />
        1.5.2 Research Process<br />
        1.5.3 Base Year<br />
        1.5.4 Report Assumptions & Caveats<br />
2 Global Isovitexin Overall Market Size<br />
    2.1 Global Isovitexin Market Size: 2022 VS 2030<br />
    2.2 Global Isovitexin Revenue, Prospects & Forecasts: 2018-2030<br />
    2.3 Global Isovitexin Sales: 2018-2030<br />
3 Company Landscape<br />
    3.1 Top Isovitexin Players in Global Market<br />
    3.2 Top Global Isovitexin Companies Ranked by Revenue<br />
    3.3 Global Isovitexin Revenue by Companies<br />
    3.4 Global Isovitexin Sales by Companies<br />
    3.5 Global Isovitexin Price by Manufacturer (2018-2023)<br />
    3.6 Top 3 and Top 5 Isovitexin Companies in Global Market, by Revenue in 2022<br />
    3.7 Global Manufacturers Isovitexin Product Type<br />
    3.8 Tier 1, Tier 2 and Tier 3 Isovitexin Players in Global Market<br />
        3.8.1 List of Global Tier 1 Isovitexin Companies<br />
        3.8.2 List of Global Tier 2 and Tier 3 Isovitexin Companies<br />
4 Sights by Product<br />
    4.1 Overview<br />
        4.1.1 By Type - Global Isovitexin Market Size Markets, 2022 & 2030<br />
        4.1.2 Min Purity Less Than 98%<br />
        4.1.3 Min Purity 98%-99%<br />
        4.1.4 Min Purity More Than 99%</p>

<div><b>Get the Complete Report & TOC @ 
            <a href="https://www.24chemicalresearch.com/reports/228751/isovitexin-market">
            https://www.24chemicalresearch.com/reports/228751/isovitexin-market</a></b></div><br>

<b>CONTACT US:</b><br>
            203A, City Vista, Fountain Road, Kharadi, Pune, India - 411014<br>
            International: +1(332) 2424 294<br>
            Asia: +91 9169162030 <br><br>
            Follow Us On LinkedIn: <a href="https://www.linkedin.com/company/24chemicalresearch/">24ChemicalResearch LinkedIn</a>